Dengue vaccine trials for phase three have begun in India. HEre is all you need to know about the dengue vaccine. Updated: August 20, 2024 6:51 PM IST By Edited by Dengue cases have been on a significant rise in India.
Monsoon season entails several mosquito borne infection that may turn fatal when not treated timely. There is no guaranteed cure for dengue, but different treatment are processed as per the severity of the case. The ICMR and Panacea Biotec have initiated the first-ever phase three clinical trial for developing a dengue vaccine in India, the Union Health Ministry said.
India’s indigenous tetravalent dengue vaccine, DengiAll, has been developed by Panacea Biotec and the first participant in this trial was vaccinated on Wednesday at the Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak. “The initiation of this phase three clinical trial for India’s first indigenous dengue vaccine marks a critical advancement in our fight against dengue. It reflects our commitment to protecting our citizens from this pervasive disease and underscores India’s capabilities in vaccine research and development,” Union Health Minister J P Nadda said.
Key Developments about Dengue Vaccine “Through this collaboration between ICMR and Panacea Biotec, we are not only taking a step towards ensuring the health and well-being of our people but also reinforcing our vision of Atmanirbhar Bharat in the healthcare sector,” he said. Panacea Biotec, one of.